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Abstract
Gut microbiota is essential for the development of the intestinal immune system,
protecting the host against pathogens and harmful inflammatory processes. Germ-free
animals have smaller Peyer's patches, fewer immune cells and impaired immunoglobu-
lin A (IgA) secretion, fewer intraepithelial lymphocytes, as well as compromised pro-
duction of antimicrobial peptides. Mucositis (mucosal barrier injury) is a major
oncological problem caused by chemotherapeutic agents. Intestinal mucositis translates
into a broad spectra of clinical symptoms (diarrhea, vomiting) and can be worsened by
neutropenia and antibiotics. Since IECs do not regulate intestinal homeostasis by them-
selves, but require symbiotic coordination with commensal bacteria and local gut leuko-
cytic cells, the role of intestinal microbiota in the development and severity of mucositis
induced by chemotherapeutic products became an issue. The present chapter reviews
the interplay between microbiota, immune system, and anticancer therapy. The
published researches in this field showed that microbiota has immunomodulatory effect
on the anticancer immune response, both in the presence and in the absence of chemo-
therapy. Animal and human studies evoked that the anticancer response depends on
microbiota variability.
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1. Introduction
The relationship between cancer and microbiota was recognized and challenged since the
nineteenth century when William Coley, a surgical oncologist, developed a mixture consisting
of killed bacteria of species Streptococcus pyogenes and Serratia marcescens, also known as
“Coley's toxin,” as a treatment for cancer.
Ever since, experimental and clinical researchers tried to isolate microbial agents or products to
treat malignant disease, such as treatment of superficial bladder cancer based on an attenuated
form of Mycobacterium bovis, an oncolytic herpes virus for the treatment of melanoma, or the
treatment of pancreatic cancer with Listeria monocytogenes [1].
The present chapter reviews the interplay between microbiota, immune system, and anticancer
therapy. The published researches in this field showed that microbiota has immunomodula-
tory effect on the anticancer immune response, both in the presence and in the absence of the
chemotherapy. Animal and human studies evoked that the anticancer response depends on
microbiota variability. In initiating an efficient chemotherapy, the following aspects should be
considered:
• The interactions between microbiota and cancer progression.
• The influence of the microbiota on the chemotherapy response.
• The microbiota imbalance influences drugs bioavailability, efficacy and toxicity.
2. Microbiota, health and diseases
Microbiota affects many physiological processes, while its alteration is thought to render a
number of pathologies.
The growing evidence regarding the importance of the microbiome for health and disease and
the host-microbe symbiosis at the immunological and metabolic levels become highly chal-
lenging for a better understanding of immunopathologies such as autoimmune and inflamma-
tory disorders. Microbiome changes were correlated with a variety of diseases such as
inflammatory bowel disease, obesity, type 2 diabetes, autism, and allergies.
Crohn's disease (CD) and ulcerative colitis (UC) are the most prevalent forms of inflammatory
bowel disease (IBD), characterized by chronic relapsing inflammation affecting the intestinal
mucosa. The etiology of these diseases is unknown, but there are increasing scientific evi-
dences that microbiota influences the pathogenesis of IBD [2].
Patients exhibit a decrease in microbial population and functional diversity, with a decrease of
Firmicutes, an increase in Bacteroidetes, and facultative anaerobes such as Enterobacteriaceae [3–5].
The intestinal microbiota was also implicated in several other gastrointestinal-related diseases,
such as obesity, type 2 diabetes, celiac disease, and colorectal cancer. The last two of these were
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associated with changes in microbiota composition, but interestingly, no pattern of alteration
was demonstrated [6–10]. Recent studies showed that the expression of the leukocyte antigen
DQ2 is a strong risk factor for the development of celiac disease. It seemed that children
possessing this haplotype also had an altered microbiota composition (compared to non-HLA
DQ2 individuals) prior to clinically apparent disease [11].
On the other hand, there is a bidirectional functional relationship between the intestine and the
kidneys, the urinary pH influencing the intestinal microbiota metabolism, while microbial-
related metabolites are involved in the development of the kidney pathologies [12].
Several studies focused on the possibility that the intestinal microbiota may influence the
hypothalamus-pituitary-adrenal (HPA) axis, and, therefore, the cognitive function and behav-
ior. HPA is a pathway activated in response to infection and perturbed by psychological
stressors (the “gut-brain axis”). There are publications that evoke a direct relationship between
enteric infections on one hand and anxiety, depression, and cognitive dysfunctions, on the
other hand [13–16].
3. Microbiota and cancer
Microbial communities inhabiting human body represent so far unknown environmental
factors that seem to have a role in carcinogenesis.
Cancer susceptibility, development, and progression result from a complex interplay between
gene regulation and the environment.
For decades, the researches on the interaction of the microbes with human organism were
focused almost exclusively on the effects of the single pathogenic microbial infection.
Several mechanisms regarding the cancer development were described for some microbial
species.
The direct carcinogen class usually comprises viruses which may produce cancer by genetic
mechanisms [17, 18].
Researches on molecular mechanisms revealed that most of the oncoproteins encoded by
human viruses target generally the tumor suppressor proteins: retinoblastoma RB1 and p53,
which play major roles in cellular anticancer protection.
Other targets reported for carcinogenesis induce by viruses involved interaction with complex
pathways of interferon signaling, transcription factors like nuclear factor-κB (NF-κB), telome-
rase complex, or cell adhesion molecules.
The Epstein-Barr virus (EBV), hepatitis C virus, and human papilloma virus are only a few
examples of the most studied oncogenic viruses.
The Epstein-Barr virus (EBV) or human herpes virus 4 (HHV-4) is one of the most common
viruses in humans and also the first discovered to be involved in tumorigenesis. The EBV
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infects immune system cells (lymphocyte B) and epithelial cells, and the infections were
correlated with some lymphoma, gastric cancer, anogenital and oropharyngeal carcinomas
and with certain autoimmune diseases [19].
Hepatitis C virus is one of the major etiologic agents of hepatocellular carcinoma [20].
Researches on HCV-specific proteins revealed that they exert multiple functions during the life
cycle of the virus. Due to their ability to adopt different structural conformations, the viral
proteins are capable of various interactions with cellular proteins interfering in signaling
pathways essential to cell functions. HCV causes genome instability suggesting that coopera-
tion of both viral and host factors plays a role in developing the disease [21, 22].
Human papillomavirus (HPV) belongs to the DNA class viruses and is capable to infect
keratinocytes of the skin and the mucosa. There are over 170 types of HPV described, and
about dozen types are considered high-risk human carcinogen producing at least six types of
cancer: cervix, penis, vulva, vagina, anus, and oropharynx [23].
The E6 and E7 genes of HPV have been identified as oncogenes involved in promoting
tumor growth and transformation to malignancy. The E6 protein is involved in
ubiquitination of p53, marking this protein for proteasomal degradation, while the protein
E7 is involved in competing the retinoblastoma protein for binding and favors the cell cycle
to continue.
The E6 and E7 deregulate the host innate immune defense required for the recruitment of the
effector immune cells. Both proteins cooperate for the downregulation of the
proinflammatory interleukins: IL-18 and IL-8 and of some chemoattractants like MCP-1 and
MIP3α. Also, proteins E6 and E7 interfere in the intracellular signaling pathways NF-κB and
interferon regulatory factors inhibiting the activation of these major antiviral transcription
factors [24].
Although molecular mechanism of cancerogenesis has been explained for some pathogenic
viruses, it is too simplistic to consider these microbes the only cause of tumorigenesis.
Cancer is a complex multistep process which evolves over time and involves many signaling
pathways and molecular interactions to generate a particular cellular phenotype.
Indirect carcinogen mechanisms comprise the injury of the epithelial barrier or inflammation
associated to some infections produced by bacterial species like Helicobacter pylori or Chlamydia
trachomatis.
Helicobacter pylori is a gram-negative pathogen which infects about half of humans all over the
world and represents the main cause for gastric cancer. The H. pylori virulence factors,
vacuolating cytotoxin (VacA) and CagA protein encoded by cytotoxin-associated gene-patho-
genicity island, are identified as major antigens. These microbial proteins interact with several
host receptors like toll-like receptor 2 (TLR2), NOD-like receptor family member NLRP3, and
caspase-1 promoting the activation of the inflammasome.
The host cellular dysfunctions on secretory system, apoptosis, and immune inhibition were
other mechanisms described as consequences of the H. pylori infection [25].
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Chlamydia trachomatis infects both men and women, but it is commonly found in the reproduc-
tive system of women. The chronic infection causes pelvic inflammation with severe conse-
quences like infertility. The incidence of infections is significant among patients with cervical
cancer, but no proof exists to demonstrate that Chlamydia itself promotes cancer. Research
proved that a common association with HPV favors cancer growth. Further studies in this
direction are necessary for confirmation.
Other experiments indicate a correlation between some commensals, the production of oxy-
gen-reactive species, and colon cancer. Thus, superoxide-producing Enterococcus faecalis was
demonstrated to cause colonic epithelial cell DNA damage [26].
Recent years’ researches focused on obesity as a risk factor for different types of cancer.
Gut microbiota plays an important role in developing obesity. Some Clostridium spp. are
microorganisms overrepresented in obese intestine and were directly correlated with liver
and colorectal cancers. These commensals convert primary bile acids into deoxycholic
acid (DCA), a carcinogen that can cause DNA damage via the production of free radicals
[27].
For a long time, scientific research describes many other potential microorganisms
involved in cancer promoting, but several questions about the main cause of tumorigenesis
were raised because of a low incidence of cancer among infected patients with susceptible
agents.
Recent researches have changed the perspective on many human diseases. Many scientific
publications in the last years sustain the fact that global changes in our microbiome are the
main causes of disease and not only a single opportunistic pathogen development.
Increased communities of Capnocytophaga gingivalis, Capnocytophaga ochracea, Eubacterium
sabureum, Leptotrichia buccalis, and Streptococcus mitis present in saliva were observed in
patients with oral squamous cell carcinoma.
Human esophageal cancer was associated in some cases with an increased presence of Strepto-
coccus anginosus, Streptococcus mitis, Treponema denticola, or some Campylobacter spp.
Salmonella typhi and S. paratyphi were increased in some bile samples collected from patients
with gall bladder cancer.
Colorectal cancer is one of the most studied regarding the microbial imbalance and molecular
mechanisms of the disease.
Cohort studies demonstrated that samples collected from patients with colon cancer presented
feces bacterial diversity with increased communities of pro-inflammatory species of
Fusobacterium and Porphyromonas and a decreased presence of Lactobacillus, Microbacterium,
Anoxybacillus, and Akkermansia muciniphila.
In colon cancer cases induced by a preexisting inflammatory colitis, microbiota played an
important role in influencing inflammation or innate immunity, genomic stability of intestinal
epithelial cells (IECs), or the release of some metabolites functioning as histone deacetylase
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inhibitors. Studies performed in gnotobiotic or in antibiotic-treated mice revealed the implica-
tion of microbes in tumorigenesis driven or not by inflammation.
4. Microbiota and immune functions
In the last years, many scientific studies demonstrated that the commensal is an important
participant to the host metabolism, inflammatory process, and immune response.
Nowadays, gut microbiota is particularly the most studied, and it has been proven to be essential
for the development of the intestinal immune system, protecting the host against pathogens and
harmful inflammatory processes. Germ-free animals have smaller Peyer's patches, fewer
immune cells and impaired immunoglobulin A (IgA) secretion, fewer intraepithelial lympho-
cytes, as well as compromised production of antimicrobial peptides [28–30].
Gut microbiota is involved in the immune responses and inflammatory processes both local
and systemic. The link between inflammation and cancer is well known raising the questions
about the potential interference of microbiota. This area of research is new, and astonishing
recent results revealed that microbiota is a key player in the immunomodulatory mechanisms
of cancer and impact of the therapeutic responsiveness [31–35].
The present knowledge sustains that the presence and the quality of gut microbiota may
induce inflammation and promote cancer or may induce tumor-destructive immune responses
and favor anticancer treatment. Most studies involved experimental animal model of trans-
plantable tumors, and only few data are sustained by clinical evidence.
The inflammation induced by microbiota may contribute to cancer by stimulating the release
of cytokines involved in the cell proliferation and apoptosis inhibition pathways.
In a study regarding a hepatocellular carcinoma mouse model, the intestinal microbiota was
essential for the promotion and initiation of cancer by signaling pathways involving toll-like
receptor 4 (TLR4), a surface immune cell receptor, which senses the microbial molecular
patterns. The activation of this receptor induced an increased level of a hepatomitogen, which
mediates the proliferative and antiapoptotic effects in tumors [36].
The beneficial immunomodulatory effect in cancer regression is supported by the use of some
microbial in anticancer therapy. The intravesical bacillus Calmette-Guerin (BCG) therapy is one
of the standard methods of management of intermediate- and high-risk non-muscle invasive
bladder cancer. Also, intratumoral inoculation of heat-killed Propionibacterium acnes in subcu-
taneous melanoma promotes local and systemic Th1 and Tc1 responses associated with tumor
regression.
More other evidences are presented and discussed by the scientific literature about the key role
of microbiota and the possibility to modulate it. However, the specific mechanisms are far to
be elucidated due to the complex composition and the multifactorial interaction between gene
and environment.
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5. Microbiota and chemotherapy
The intestinal epithelium is a single-cell layer, which functions as the largest barrier of the
human body. It is characterized by a selective permeability for the nutrients, electrolytes, and
water and has an effective role in defense against toxins and enteric microbiota. Intestinal
epithelial cells maintain the local environmental balance by facilitating the interaction between
commensal and the host immune cells [37].
In order to obtain the best anticancer drug bioavailability, the formulation must consider besides
the physicochemical properties or drug adjuvants, the permeability of the intestinal barrier.
Mucositis (mucosal barrier injury) is a major oncological problem caused by chemotherapeutic
agents. Intestinal mucositis translates into a broad spectra of clinical symptoms (diarrhea,
vomiting) and can be worsened by neutropenia and antibiotics. Since IECs do not regulate
intestinal homeostasis by themselves, but require symbiotic coordination with commensal
bacteria and local gut leukocytic cells, the role of intestinal microbiota in the development
and severity of mucositis induced by chemotherapeutic products became an issue [38].
5.1. Cyclophosphamide (CTX)
Cyclophosphamide (CTX) is an alkylating agent commonly used in combination with other
therapies to target cancer cells.
The importance of gut microbiota in efficacy of the treatment is sustained by studies involving
germ-free (GF) mice and specific-pathogen-free (SPF) mice with transplantable MCA205 sar-
comas. A significant decrease effect of the CTX treatment was obtained in case of GF animals
in comparison with SPF mice [22].
Similar effects comparing to untreated control groups were obtained in case of the animal
treatment with vancomycin A, an antibiotic that destroys the gram-positive bacteria. The
results indicate that the presence of some bacteria creates an immunologic local environment
essential for the therapeutic effect of CTX [39].
5.2. CpG oligodeoxynucleotides
The cytosine phosphodiester-linked guanine (CpG) oligodeoxynucleotides (CpG-ODN)
are synthetic compounds with immunostimulatory effect used for enhancing the anticancer
treatments. Preclinical and clinical study demonstrated a synergy between these drugs and
monoclonal antibody and can be safely administrated together for a better therapeutic
response [40–42].
The microbial DNA contains unmethylated cytosine phosphodiester-linked guanine (CpG)
motifs which are recognized by specific immune receptors of the host-like human toll-like
receptor 9 (TLR9) present on the surface of different immune cell types. Activation of these
receptors enhances the expression of proinflammatory cytokines.
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Researches on mouse models with transplantable tumors revealed that the intratumoral
administration of the CpG-ODN and a monoclonal antibody (anti-interleukin-10 antibodies)
induce hemorrhagic necrosis. This stimulatory immune response was mediated by tumor
necrosis factor (TNF) and other inflammatory cytokines [40].
A study published in 2013 in Science using experimental model of tumor-infiltrating myeloid-
derived cells on antibiotic-treated and GF mice remarkably revealed that the animals were
refractory to therapy with CpG-ODN and anti-IL-10 antibody and presented low levels of TNF
and cytokines required for promoting the hemorrhagic necrosis. A therapeutic response was
obtained after the administration of lipopolysaccharides, a ligand for the TLR9 receptors-like.
No response was obtained on TLR9-deficient mice [39].
Furthermore, study on the composition of mouse microbiota demonstrated that Alistipes shahii
is positively correlated with TNF production in the tumor, whereas the abundance of Lactoba-
cillus fermentum negatively correlated with it.
Thus, the research sustains the importance of the intact commensal microbiota for an optimal
responses to cancer therapy required for the modulation myeloid-derived cell functions in the
tumor microenvironment [22, 41].
5.3. Platinum salts
Platinum salts are coordination complexes of platinum used as chemotherapeutic drugs. Cis-
platin and oxaliplatin interfere with DNA repair mechanism inducing intrastrand cross-link
adducts activating the proapoptotic pathways. The platinum compound effect depends also by
the presence of reactive oxygen species (ROS) for an apoptotic response and DNA damage.
Lida et al. presented evidence in the same study involving CpG-ODN that the therapeutic
effect of the platinum salts on transplanted subcutaneous tumor depends on the presence of
mice microbiota. The authors sustained that the ROS required for the genotoxic effect of these
chemotherapies are produced in vivo by inflammatory cells associated to the tumor [41].
GF mice and antibiotic treatment attenuated the pharmacological effect and reduced the
expression of ROS-responsive genes.
Moreover, using transgenic mice deficient for the myeloid NADPH oxidase NOX2 (Cybb_/_)
with a low ROS response, the effect of oxaliplatin was attenuated.
The study highlights the importance of commensal on an efficient therapy by its contribution
to tumor reduction.
5.4. Immune checkpoint blockade therapy
The problem of the therapeutic response variability was the starting point of recent researches
which deal with the importance of microbiota in case of the patients treated with monoclonal
antibodies involved in the immune checkpoint blockade.
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Ipilimumab is an immunoglobulin G1 targeting the cytotoxic T-lymphocyte-associated protein
4 (CTLA4), which is a receptor protein involved in the immune checkpoint system and
downregulation of the immune response.
The efficacy of the CTLA4 blockade was associated with T-lymphocyte responses induced by
Bacteroides thetaiotaomicron and Bacteroides fragilis in both experimental models and human. No
tumoral response was noticed after the treatment with ipilimumab in case of antibiotic treat-
ment and germ-free mice. Exposure to B. fragilis, its polysaccharides, or its specific T cells
reversed the response and favored the anticancer effect. The author of the study concluded
that some Bacteroides spp. may play an important role and that the colitis may even antagonize
the therapeutic efficacy [42].
Anti-PD-L1 is a monoclonal antibody successfully used for the treatment of several solid
tumors, which target the protein programmed death-ligand 1 (PD-L1).
PD-L1 is a transmembrane protein, which acts as suppressor of the immune system and plays
a role in escaping the cancer cells to immune system.
Sivan et al. demonstrated in their study that the commensal Bifidobacterium may have an
unexpected role in enhancing antitumor immunity in vivo [43].
The authors used for research an experimental model of subcutaneous B16.SIY melanoma
growth in genetically similar C57BL/6 mice. The animals were provided by two different
animal facilities. After the anti-PD-L1 treatment, the results differ according to the animal
provider. The Bifidobacterium spp. were identified by sequencing of the 16S ribosomal RNA
and were correlated with the antitumor response therapy. The oral administration of bacteria
improved tumor control to the same degree as anti-PD-L1, and the association of the microor-
ganisms with this drug nearly abolished tumor outgrowth [22–43].
6. Conclusions
Even though there are increasing evidences regarding the close relationship between tumor
development, chemotherapy, microbiota, and the immune system, it is still difficult and
speculative to consider the microbes when deciding the therapeutic strategy for patients.
However, modulating microbiota may enhance drug efficacy or diminish chemotherapy's
toxicity.
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